

## Response To Oral Agents in Diabetes -Pilot Study (ROAD)

### Reporting Groups

	Description
<b>Gliclazide MR</b>	Gliclazide MR: 30mg daily increased to 60mg if HbA1c > 7% at 3 months
<b>Sitagliptin</b>	Sitagliptin: Sitagliptin 100mg daily for 6 months
<b>Pioglitazone</b>	Pioglitazone: Pioglitazone 30mg daily , increased to 45mg daily if HbA1c >7% at 3 months. 6 months duration
<b>Metformin</b>	Metformin: Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment

### Participant Flow: Overall Study

	Gliclazide MR	Sitagliptin	Pioglitazone	Metformin
<b>STARTED</b>	6	6	6	11
<b>COMPLETED</b>	6	6	6	11
<b>NOT COMPLETED</b>	0	0	0	0

### Baseline Measures

	Gliclazide MR	Sitagliptin	Pioglitazone	Metformin	Total
<b>Overall Participants Analyzed</b> [Units: Participants]	6	6	6	11	29

<b>Age</b> [Units: Years] Mean (Standard Deviation)	62.4 (4.6)	61.5 (9.9)	61.3 (11.8)	59.6 (8.8)	60.9 (9.2)
---	------------	------------	-------------	------------	------------

<b>Sex: Female, Male</b> [Units: Participants] Count of Participants					
<b>Female</b>	3 50.0%	3 50.0%	2 33.3%	6 54.5%	14 48.3%
<b>Male</b>	3 50.0%	3 50.0%	4 66.7%	5 45.5%	15 51.7%

<b>Region of Enrollment</b> [Units: Participants] Count of Participants					
<b>United Kingdom</b>	6	6	6	11	29